Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Anaptysbio (ANAB) over the last 11 years, with Q3 2025 value amounting to $2.9 million.

  • Anaptysbio's Accounts Payables fell 1945.99% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 1945.99%. This contributed to the annual value of $4.0 million for FY2024, which is 1481.48% down from last year.
  • Anaptysbio's Accounts Payables amounted to $2.9 million in Q3 2025, which was down 1945.99% from $3.3 million recorded in Q2 2025.
  • Anaptysbio's 5-year Accounts Payables high stood at $6.5 million for Q3 2023, and its period low was $1.6 million during Q2 2022.
  • Moreover, its 5-year median value for Accounts Payables was $3.6 million (2024), whereas its average is $3.8 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first crashed by 7139.19% in 2021, then soared by 20000.0% in 2023.
  • Quarter analysis of 5 years shows Anaptysbio's Accounts Payables stood at $1.7 million in 2021, then surged by 59.91% to $2.8 million in 2022, then surged by 68.75% to $4.7 million in 2023, then dropped by 14.81% to $4.0 million in 2024, then dropped by 27.71% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $3.3 million for Q2 2025, and $6.1 million during Q1 2025.